Skip to main content
OpenTrials
Completed

NCT Number: NCT02292524

Prostate Biomarkers in Men Consuming Tomato Products

Prostate Biomarkers in Men Consuming Tomato Products

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

The Ohio State University Comprehensive Cancer Center/ We

Columbus, Ohio, 43210, United States

About this study

Participants completed a minimum week-long washout period without consumption of tomato products prior to randomization to one of four dietary interventions. Men were randomized to one of the following dietary interventions: a controlled low lycopene diet (≤ 5 mg/d from foods), daily Prego® spaghetti sauce, daily V8® vegetable juice, or daily Campbell's® Tomato Soup. Each of the tomato products provided between 25 and 35 mg lycopene per day. In order to provide this dietary intervention in typical serving sizes in the context of a usual diet but devoid of other tomato sources, participants kept daily logs documenting compliance with the intervention product and a tomato-restricted diet from enrollment to the day of surgery (~3 weeks). Study participants were asked to complete an abbreviated dietary history questionnaire (to establish typical consumption patterns of various tomato products) and two separate 3-day diet food records, once during the washout and once during the intervention period. Blood and 24-hour urine samples were obtained at two time points, after the one-week washout phase and at the end of the dietary intervention period. Fresh prostate samples were obtained at time of surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

To be included in this study, men must:

  • Have biopsy-proven, clinically localized adenocarcinoma of the prostate based on standard presurgical staging studies
  • Have chosen to undergo a radical prostatectomy for treatment of their disease after the medical team has presented all possible treatment options
  • Have kidney and liver enzymes, CBC, and PT/PTT/INR within normal limits
  • Agree to sign consent form prior to enrollment in the study

Exclusion criteria

Men may not participate in this if they:

  • Are currently taking lycopene or "alternative" dietary supplements
  • Have a history of digestive or malabsorptive disorders, metabolic enzyme deficiencies, or other disorders requiring special dietary modifications (controlled type II diabetes mellitus was allowed)

Treatment and study plan

Commercially-available tomato food product

Other

Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.

Primary outcomes

  1. Measure carotenoids, including lycopene and its isomers, in blood (umol/L) and prostate tissue (nmol/g) of men after three weeks of consuming V8 vegetable juice, condensed tomato soup or tomato sauce.

    Time frame: Day 0 and End of Study (an average of 23 days)

Secondary outcomes

  1. Measure histobiomarkers in the prostate related to aggressive disease including Gleason Grade (number 1 - 10), tumor volume (weight) , and vascular endothelial growth factor expression (ng/mL)

    Time frame: Day 0 and End of Study (an average of 23 days)

    Measure histobiomarkers in the prostate related to aggressive disease including Gleason Grade, tumor volume, and vascular endothelial growth factor expression

  2. Measure biomarkers related to prostate cancer in controls and men consuming tomato food products prior to surgery. These biomarkers include plasma insulin like growth factor (ng/mL) and plasma prostate specific antigen (ng/mL)

    Time frame: Day 0 and End of study (an average of 23 days)

    Measure biomarkers related to prostate cancer in controls and men consuming tomato food products prior to surgery. These biomarkers include plasma insulin like growth factor (ng/mL) and plasma prostate specific antigen (ng/mL)

Sponsors and collaborators

Lead sponsor

Ohio State University Comprehensive Cancer Center

Other

Collaborators

  • Schwartz, Steven, PhD

Registry information

Important dates

Study start
2002
Primary completion
2004
Study completion
2004
First posted
Nov 17, 2014
Registry last updated
Nov 17, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.